Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.70 |
| ▸ | PPARG | P37231 | 3/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 2/20 | 0.60 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.60 |
| ▸ | FABP2 | P12104 | 1/20 | 0.60 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.54 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11639708 | 0.95 | PPARA (0.64) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL12634744 | 0.92 | PPARA (0.74) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL11471320 | 0.90 | PPARA (0.58) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL4425860 | 0.86 | MAOB (0.58) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL135713 | 0.82 | PPARA (0.72) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL9372364 | 0.82 | PPARA (0.72) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| Clofibric Acid SCHEMBL102826 | 0.82 | PPARA (1.00) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL4000649 | 0.82 | PPARA (0.47) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| SCHEMBL3948925 | 0.82 | PPARA (0.47) | PPARACYP1A2CYP3A4CYP2C19MAPT | |
| Clofibric Acid SCHEMBL2227936 | 0.82 | PPARA (1.00) | PPARACYP1A2CYP3A4CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910309-A2 | CYCLOALKYL AMINO-HYDANTOIN COMPOUNDS AND USE THEREOF FOR ß-SECRETASE MODULATION | Wyeth (US) | 2008-04-16 | — | — | EP | claimed |
| WO-2007016012-A2 | CYCLOALKYL AMINO-HYDANTOIN COMPOUNDS AND USE THEREOF FOR β-SECRETASE MODULATION | WYETH (US) | 2007-02-08 | — | — | WO | claimed |
| US-12042531-B2 | Breast and ovarian cancer vaccines | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2024-07-23 | — | — | US | disclosed |
| WO-2024151904-A2 | METHODS AND COMPOSITIONS FOR SCREENING AND TREATING ALZHEIMER'S DISEASE | POPULATION BIO, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-12012634-B2 | Methods for diagnosing, prognosing, and treating parkinson's disease or parkinsonism | POPULATION BIO, INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-20240156961-A1 | TISSUE-SPECIFIC ANTIGENS FOR CANCER IMMUNOTHERAPY | BIONTECH US INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4177356-B1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML SCREENING LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-3577236-B1 | METHODS FOR ASSESSING RISK OF DEVELOPING A VIRAL DISEASE USING A GENETIC TEST | PML SCREENING LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-11920199-B2 | Methods and compositions for screening and treating developmental disorders | THE HOSPITAL FOR SICK CHILDREN (CA) | 2024-03-05 | — | — | US | disclosed |
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | CRITITECH, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-11913073-B2 | Methods for assessing risk of developing a viral disease using a genetic test | PML SCREENING, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-20040259880-A1 | Pyrrole compounds and uses thereof | AMBIT BIOSCIENCES CORPORATION (US) | 2004-12-23 | — | — | US | disclosed |
| US-20040248957-A1 | Heterocyclic compounds and uses thereof | AMBIT BIOSCIENCES CORPORATION | 2004-12-09 | — | — | US | disclosed |
| US-20040248972-A1 | Compounds and uses thereof | AMBIT BIOSCIENCES CORPORATION | 2004-12-09 | — | — | US | disclosed |
| WO-2004103959-A2 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004103960-A2 | COMPOUNDS AND USES THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2004-12-02 | — | — | WO | disclosed |
| US-20040242673-A1 | Heterocyclic compounds and uses thereof | AMBIT BIOSCIENCES CORPORATION | 2004-12-02 | — | — | US | disclosed |
| EP-1446110-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | Structural Bioinformatics Inc. (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2003077847-A2 | SUBSTITUTED AMIDES | MERCK & CO., INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| WO-2003032916-A2 | ORGANOSULFUR INHIBITORS OF TYROSINE PHOSPHATASES | STRUCTURAL BIOINFORMATICS INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918691-B2 | Local delivery of antineoplastic particles in combination with systemic delivery of immunotherapeutic agents for the treatment of cancer | ARID2, ACIN1, TP53 | PPARA 734/4885CYP1A2 4750/4885CYP3A4 4854/4885 |
| US-20040248972-A1 | Compounds and uses thereof | HMGCR, PCSK9, CYP46A1 | PPARA 284/4885CYP1A2 439/4885CYP3A4 231/4885 |
| US-20040248957-A1 | Heterocyclic compounds and uses thereof | PDE7A, PDE3B, PDE7B | PPARA 1593/4885CYP1A2 635/4885CYP3A4 435/4885 |
| US-20040259880-A1 | Pyrrole compounds and uses thereof | PYCR1, PARK7, PPOX | PPARA 92/4885CYP1A2 3362/4885CYP3A4 3506/4885 |
| US-20040242673-A1 | Heterocyclic compounds and uses thereof | HTT, PARK7, FDPS | PPARA 814/4885CYP1A2 1141/4885CYP3A4 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.